pubmed:abstractText |
Due to the heterogeneous biologic behavior of stage T1 bladder carcinomas, there is a need for new markers allowing to assess the prognosis more accurately. To our knowledge, there are no reports on studies investigating minichromosome maintenance protein 2 (MCM2) expression in bladder carcinomas. Thus, we investigated the prognostic value of MCM2 immunoreactivity in stage T1 bladder tumors.
|
pubmed:affiliation |
Institute of Pathology, University of Lübeck, Ratzeburger Allee 160, D-23538, Lübeck, Germany. krueger@patho.mu-luebeck.de
|